Why Most Cancer Treatment Personalization Fails — And How to Fix It

The 30% Problem

Here's a number that should scare every oncologist: only 30% of cancer patients eligible for targeted therapy actually receive it. Not because the drugs don't exist — they do. Not because the mutations aren't detectible — they are. The bottleneck is purely operational.

For over a decade, precision oncology has been billed as the future of cancer care. Sequence the tumor, find the genetic driver, match it to a targeted drug. The science has been solved for years. What's still missing is the operational layer that gets genomic insights from the sequencing lab to the treatment chair in time to matter.

Where Programs Actually Succeed

Organizations that have scaled precision oncology beyond pilot programs share a common pattern: they treat genomics data infrastructure as a first-class clinical system, not a research project.

The Integration Layer

The first challenge isn't sequencing — it's integration. Mayo Clinic's oncology informatics team has shown that the critical success factor is pushing genomic results directly into the EHR at the point of care, with structured biomarker summaries oncologists can act on immediately.

What this means in practice:

• Genomic reports integrated into the treatment plan view within 72 hours of sequencing
• Actionable mutations flagged with FDA-approved targeted therapies
• Clinical decision support firing at the point of prescription, not after

Organizations without this layer have genomic data that oncologists never see in time to influence treatment decisions.

Real-World Evidence Integration

The second shift is moving beyond single-trial evidence to real-world evidence integration. The key insight: clinical trial populations don't represent real-world patient populations. Building personalized treatment protocols requires:

• Post-market surveillance data feeding back into treatment algorithms
• Outcomes tracking that closes the loop from prescription to response
• Adaptive protocols that evolve based on what's actually working

MD Anderson and other leading centers have pioneered this approach, showing response rate improvements of 20-30% when real-world evidence supplements trial data.

The Protocol Building Block

The third pattern is protocol standardization. Organizations succeeding at scale have moved past ad-hoc molecular tumor boards to structured protocols that:

• Define biomarker thresholds triggering specific treatment pathways
• Specify validation requirements before treatment decisions
• Automate the correlation between detected mutations and approved therapies

This isn't cookbook medicine — it's enabling oncologists to make informed decisions faster by removing the interpretation burden.

The Financial Reality

Precision oncology programs fail financially when they're treated as standalone genomics initiatives. The sustainable model treats genomics infrastructure as a system-wide investment:

• Shared analytics platforms across tumor types
• Centralized variant interpretation services
• Standardized data pipelines that reduce per-test overhead

Organizations we've worked with see 3-5x ROI within 18 months when they build for scale from day one.

What Oncologists Actually Need

Talk to oncologists in practices that have scaled precision oncology, and the feedback is consistent: they don't need more genomic data — they need decision-support that works within their existing workflow.

The difference between programs that stuck and programs that scaled comes down to whether the genomics team built for oncologists or built for researchers.

The Path Forward

The organizations that will lead in oncology over the next decade aren't the ones with the most sequencing capacity — they're the ones who've solved the operational integration challenge.

This means:

1. Investing in EHR integration before investing in new sequencing technology
2. Building real-world evidence infrastructure alongside clinical trials
3. Standardizing protocols that scale across tumor types
4. Tracking outcomes to close the loop on treatment decisions

The science of precision oncology is solved. The operational challenge is what separates programs that deliver on the promise from ones that become cautionary tales.

---

Pi Data Science helps healthcare organizations operationalize precision oncology programs — from NGS pipeline optimization to EHR integration to protocol design. We work with oncology teams ready to move beyond pilots to scalable programs. Reach out to learn how we can help build yours.